Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$97.13M
EBITDA Margin
-4034.35%
TTM Avg
-4034.35%
3Y Avg
-3775.34%
5Y Avg
-2903.14%
Market Cap
$97.84M
EBITDA Margin
-1299.47%
TTM Avg
-2594.80%
3Y Avg
-2594.80%
5Y Avg
-1753.28%
Market Cap
$93.28M
EBITDA Margin
5.05%
TTM Avg
6.33%
3Y Avg
5.80%
5Y Avg
5.80%
Market Cap
$91.33M
EBITDA Margin
-35.83%
TTM Avg
-39.56%
3Y Avg
-111.97%
5Y Avg
-250.85%
Market Cap
$90.42M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$90.73M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $97.80M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.13M | -4034.35% | -4034.35% | -3775.34% | -2903.14% |
| Korro Bio, Inc. (KRRO)vs › | $97.84M | -1299.47% | -2594.80% | -2594.80% | -1753.28% |
| PolyPid Ltd. (PYPD)vs › | $98.56M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.28M | 5.05% | 6.33% | 5.80% | 5.80% |
| Biomea Fusion, Inc. (BMEA)vs › | $92.20M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.33M | -35.83% | -39.56% | -111.97% | -250.85% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $90.42M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $90.73M | -19.79% | -29.84% | -150.95% | -150.95% |
| The Joint Corp. (JYNT)vs › | $102.85M | 1.47% | 3.45% | 8.31% | 9.97% |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
